MSL DAILY PHARMA NEWS - Merck's next-gen pneumococcal vaccine scores in phase 3 amid race with Pfizer #Prizer #Pneumococcal “In the race between two pharma giants in a multibillion-dollar field, Merck Monday posted two trial wins. With the data, the drugmaker is preparing to file its next-gen pneumococcal vaccine candidate, V114, with regulators worldwide. Merck's 15-valent vaccine candidate met its objectives in two phase 3 studies in certain patient populations, the New Jersey drugmaker said. One study tested the vaccine candidate in patients 18 and older who are living with HIV, and the other focused on patients 50 and older who also received a quadrivalent flu vaccine. In the first study, V114 elicited an immune response against all 15 serotypes included in the shot. The second study showed that the vaccine can be given at the same time as a quadrivalent flu vaccine, Merck said. “ Free webinar on “how to become an MSL” https://lnkd.in/gFYBJ2G Or click on our profile. Click below to read further, like and share it and follow us to learn more. Our Medical Science Liaison testimonials: Http://https://lnkd.in/eEfHu4c #MSL #FSTP #MSLcert #medicalscienceliaison https://lnkd.in/dp3e3V4 https://www.instagram.com/p/CB4dhDDDbYT/?igshid=5tslslxh0kz8